nodes	percent_of_prediction	percent_of_DWPC	metapath
Disopyramide—SLC22A1—hematologic cancer	0.306	1	CbGaD
Disopyramide—SLC22A2—Daunorubicin—hematologic cancer	0.0413	0.0938	CbGbCtD
Disopyramide—ORM1—Imatinib—hematologic cancer	0.0383	0.0869	CbGbCtD
Disopyramide—SLC22A2—Cytarabine—hematologic cancer	0.0364	0.0828	CbGbCtD
Disopyramide—SLC22A2—Cladribine—hematologic cancer	0.0344	0.0782	CbGbCtD
Disopyramide—SLC22A1—Cytarabine—hematologic cancer	0.0317	0.0719	CbGbCtD
Disopyramide—SLC22A2—Imatinib—hematologic cancer	0.0316	0.0719	CbGbCtD
Disopyramide—SLC22A1—Cladribine—hematologic cancer	0.0299	0.0679	CbGbCtD
Disopyramide—SLC22A1—Imatinib—hematologic cancer	0.0275	0.0624	CbGbCtD
Disopyramide—SLC22A2—Vinblastine—hematologic cancer	0.0176	0.0399	CbGbCtD
Disopyramide—SLC22A2—Cisplatin—hematologic cancer	0.0161	0.0366	CbGbCtD
Disopyramide—CYP3A4—Bexarotene—hematologic cancer	0.0112	0.0255	CbGbCtD
Disopyramide—CYP3A4—Lomustine—hematologic cancer	0.0104	0.0237	CbGbCtD
Disopyramide—CYP3A4—Busulfan—hematologic cancer	0.0104	0.0237	CbGbCtD
Disopyramide—CYP3A4—Thiotepa—hematologic cancer	0.00931	0.0211	CbGbCtD
Disopyramide—CYP3A4—Methoxsalen—hematologic cancer	0.00724	0.0164	CbGbCtD
Disopyramide—CYP3A4—Bortezomib—hematologic cancer	0.00689	0.0156	CbGbCtD
Disopyramide—CYP3A4—Daunorubicin—hematologic cancer	0.00659	0.015	CbGbCtD
Disopyramide—CYP3A4—Cytarabine—hematologic cancer	0.00581	0.0132	CbGbCtD
Disopyramide—CYP3A4—Teniposide—hematologic cancer	0.00572	0.013	CbGbCtD
Disopyramide—CYP3A4—Ifosfamide—hematologic cancer	0.00528	0.012	CbGbCtD
Disopyramide—CYP3A4—Imatinib—hematologic cancer	0.00505	0.0115	CbGbCtD
Disopyramide—CYP3A4—Ruxolitinib—hematologic cancer	0.00475	0.0108	CbGbCtD
Disopyramide—CYP3A4—Nilotinib—hematologic cancer	0.00458	0.0104	CbGbCtD
Disopyramide—CYP3A4—Vinorelbine—hematologic cancer	0.00455	0.0103	CbGbCtD
Disopyramide—CYP3A4—Triamcinolone—hematologic cancer	0.00416	0.00945	CbGbCtD
Disopyramide—CYP3A4—Dasatinib—hematologic cancer	0.00405	0.00921	CbGbCtD
Disopyramide—CYP3A4—Mitoxantrone—hematologic cancer	0.004	0.00909	CbGbCtD
Disopyramide—CYP3A4—Betamethasone—hematologic cancer	0.00357	0.0081	CbGbCtD
Disopyramide—CYP3A4—Prednisolone—hematologic cancer	0.00352	0.008	CbGbCtD
Disopyramide—CYP3A4—Prednisone—hematologic cancer	0.00332	0.00755	CbGbCtD
Disopyramide—CYP3A4—Irinotecan—hematologic cancer	0.00315	0.00716	CbGbCtD
Disopyramide—CYP3A4—Vinblastine—hematologic cancer	0.0028	0.00637	CbGbCtD
Disopyramide—CYP3A4—Vincristine—hematologic cancer	0.00275	0.00626	CbGbCtD
Disopyramide—CYP3A4—Etoposide—hematologic cancer	0.00252	0.00573	CbGbCtD
Disopyramide—CYP3A4—Dexamethasone—hematologic cancer	0.00208	0.00471	CbGbCtD
Disopyramide—CYP3A4—Doxorubicin—hematologic cancer	0.00172	0.00391	CbGbCtD
Disopyramide—Body temperature increased—Etoposide—hematologic cancer	3.85e-05	0.000194	CcSEcCtD
Disopyramide—Vertigo—Prednisone—hematologic cancer	3.84e-05	0.000194	CcSEcCtD
Disopyramide—Hepatitis—Epirubicin—hematologic cancer	3.84e-05	0.000194	CcSEcCtD
Disopyramide—Syncope—Prednisone—hematologic cancer	3.84e-05	0.000194	CcSEcCtD
Disopyramide—Hypoaesthesia—Epirubicin—hematologic cancer	3.82e-05	0.000193	CcSEcCtD
Disopyramide—Vomiting—Vincristine—hematologic cancer	3.82e-05	0.000193	CcSEcCtD
Disopyramide—Anorexia—Betamethasone—hematologic cancer	3.82e-05	0.000193	CcSEcCtD
Disopyramide—Anorexia—Dexamethasone—hematologic cancer	3.82e-05	0.000193	CcSEcCtD
Disopyramide—Urticaria—Prednisolone—hematologic cancer	3.82e-05	0.000193	CcSEcCtD
Disopyramide—Asthenia—Cisplatin—hematologic cancer	3.81e-05	0.000193	CcSEcCtD
Disopyramide—Fatigue—Triamcinolone—hematologic cancer	3.81e-05	0.000192	CcSEcCtD
Disopyramide—Rash—Vincristine—hematologic cancer	3.79e-05	0.000191	CcSEcCtD
Disopyramide—Dermatitis—Vincristine—hematologic cancer	3.79e-05	0.000191	CcSEcCtD
Disopyramide—Pain—Triamcinolone—hematologic cancer	3.78e-05	0.000191	CcSEcCtD
Disopyramide—Headache—Vincristine—hematologic cancer	3.77e-05	0.00019	CcSEcCtD
Disopyramide—Loss of consciousness—Prednisone—hematologic cancer	3.76e-05	0.00019	CcSEcCtD
Disopyramide—Hypotension—Betamethasone—hematologic cancer	3.75e-05	0.000189	CcSEcCtD
Disopyramide—Hypotension—Dexamethasone—hematologic cancer	3.75e-05	0.000189	CcSEcCtD
Disopyramide—Nausea—Carmustine—hematologic cancer	3.74e-05	0.000189	CcSEcCtD
Disopyramide—Vomiting—Mitoxantrone—hematologic cancer	3.72e-05	0.000188	CcSEcCtD
Disopyramide—Vomiting—Irinotecan—hematologic cancer	3.72e-05	0.000188	CcSEcCtD
Disopyramide—Nausea—Alitretinoin—hematologic cancer	3.71e-05	0.000187	CcSEcCtD
Disopyramide—Agranulocytosis—Doxorubicin—hematologic cancer	3.7e-05	0.000187	CcSEcCtD
Disopyramide—Rash—Mitoxantrone—hematologic cancer	3.69e-05	0.000186	CcSEcCtD
Disopyramide—Rash—Irinotecan—hematologic cancer	3.69e-05	0.000186	CcSEcCtD
Disopyramide—Dermatitis—Mitoxantrone—hematologic cancer	3.69e-05	0.000186	CcSEcCtD
Disopyramide—Dermatitis—Irinotecan—hematologic cancer	3.69e-05	0.000186	CcSEcCtD
Disopyramide—Headache—Mitoxantrone—hematologic cancer	3.67e-05	0.000185	CcSEcCtD
Disopyramide—Headache—Irinotecan—hematologic cancer	3.67e-05	0.000185	CcSEcCtD
Disopyramide—Nausea—Ifosfamide—hematologic cancer	3.66e-05	0.000185	CcSEcCtD
Disopyramide—Feeling abnormal—Triamcinolone—hematologic cancer	3.64e-05	0.000184	CcSEcCtD
Disopyramide—Diarrhoea—Cisplatin—hematologic cancer	3.64e-05	0.000184	CcSEcCtD
Disopyramide—Vomiting—Gemcitabine—hematologic cancer	3.63e-05	0.000183	CcSEcCtD
Disopyramide—Insomnia—Betamethasone—hematologic cancer	3.62e-05	0.000183	CcSEcCtD
Disopyramide—Insomnia—Dexamethasone—hematologic cancer	3.62e-05	0.000183	CcSEcCtD
Disopyramide—Bradycardia—Doxorubicin—hematologic cancer	3.62e-05	0.000183	CcSEcCtD
Disopyramide—Paraesthesia—Dexamethasone—hematologic cancer	3.6e-05	0.000182	CcSEcCtD
Disopyramide—Paraesthesia—Betamethasone—hematologic cancer	3.6e-05	0.000182	CcSEcCtD
Disopyramide—Discomfort—Prednisone—hematologic cancer	3.6e-05	0.000182	CcSEcCtD
Disopyramide—Rash—Gemcitabine—hematologic cancer	3.6e-05	0.000182	CcSEcCtD
Disopyramide—Dermatitis—Gemcitabine—hematologic cancer	3.59e-05	0.000181	CcSEcCtD
Disopyramide—Headache—Gemcitabine—hematologic cancer	3.57e-05	0.00018	CcSEcCtD
Disopyramide—Nausea—Vincristine—hematologic cancer	3.57e-05	0.00018	CcSEcCtD
Disopyramide—Hepatitis—Doxorubicin—hematologic cancer	3.56e-05	0.00018	CcSEcCtD
Disopyramide—Hypoaesthesia—Doxorubicin—hematologic cancer	3.54e-05	0.000179	CcSEcCtD
Disopyramide—Dyspepsia—Dexamethasone—hematologic cancer	3.53e-05	0.000178	CcSEcCtD
Disopyramide—Dyspepsia—Betamethasone—hematologic cancer	3.53e-05	0.000178	CcSEcCtD
Disopyramide—Urticaria—Triamcinolone—hematologic cancer	3.51e-05	0.000177	CcSEcCtD
Disopyramide—Dysgeusia—Methotrexate—hematologic cancer	3.5e-05	0.000177	CcSEcCtD
Disopyramide—Asthenia—Etoposide—hematologic cancer	3.49e-05	0.000176	CcSEcCtD
Disopyramide—Body temperature increased—Triamcinolone—hematologic cancer	3.49e-05	0.000176	CcSEcCtD
Disopyramide—Oedema—Prednisone—hematologic cancer	3.49e-05	0.000176	CcSEcCtD
Disopyramide—Decreased appetite—Dexamethasone—hematologic cancer	3.48e-05	0.000176	CcSEcCtD
Disopyramide—Decreased appetite—Betamethasone—hematologic cancer	3.48e-05	0.000176	CcSEcCtD
Disopyramide—Nausea—Mitoxantrone—hematologic cancer	3.48e-05	0.000176	CcSEcCtD
Disopyramide—Nausea—Irinotecan—hematologic cancer	3.48e-05	0.000176	CcSEcCtD
Disopyramide—Fatigue—Dexamethasone—hematologic cancer	3.46e-05	0.000175	CcSEcCtD
Disopyramide—Fatigue—Betamethasone—hematologic cancer	3.46e-05	0.000175	CcSEcCtD
Disopyramide—Pruritus—Etoposide—hematologic cancer	3.45e-05	0.000174	CcSEcCtD
Disopyramide—Shock—Prednisone—hematologic cancer	3.43e-05	0.000173	CcSEcCtD
Disopyramide—Arrhythmia—Epirubicin—hematologic cancer	3.43e-05	0.000173	CcSEcCtD
Disopyramide—Pain—Dexamethasone—hematologic cancer	3.43e-05	0.000173	CcSEcCtD
Disopyramide—Pain—Betamethasone—hematologic cancer	3.43e-05	0.000173	CcSEcCtD
Disopyramide—Skin disorder—Prednisone—hematologic cancer	3.39e-05	0.000171	CcSEcCtD
Disopyramide—Nausea—Gemcitabine—hematologic cancer	3.39e-05	0.000171	CcSEcCtD
Disopyramide—Vomiting—Cisplatin—hematologic cancer	3.38e-05	0.000171	CcSEcCtD
Disopyramide—Hyperhidrosis—Prednisone—hematologic cancer	3.37e-05	0.00017	CcSEcCtD
Disopyramide—Vision blurred—Methotrexate—hematologic cancer	3.37e-05	0.00017	CcSEcCtD
Disopyramide—Rash—Cisplatin—hematologic cancer	3.35e-05	0.000169	CcSEcCtD
Disopyramide—Dermatitis—Cisplatin—hematologic cancer	3.35e-05	0.000169	CcSEcCtD
Disopyramide—Diarrhoea—Etoposide—hematologic cancer	3.33e-05	0.000168	CcSEcCtD
Disopyramide—Anorexia—Prednisone—hematologic cancer	3.33e-05	0.000168	CcSEcCtD
Disopyramide—Ill-defined disorder—Methotrexate—hematologic cancer	3.32e-05	0.000167	CcSEcCtD
Disopyramide—Feeling abnormal—Betamethasone—hematologic cancer	3.3e-05	0.000167	CcSEcCtD
Disopyramide—Feeling abnormal—Dexamethasone—hematologic cancer	3.3e-05	0.000167	CcSEcCtD
Disopyramide—Flatulence—Epirubicin—hematologic cancer	3.3e-05	0.000166	CcSEcCtD
Disopyramide—Tension—Epirubicin—hematologic cancer	3.28e-05	0.000166	CcSEcCtD
Disopyramide—Dysgeusia—Epirubicin—hematologic cancer	3.28e-05	0.000165	CcSEcCtD
Disopyramide—Nervousness—Epirubicin—hematologic cancer	3.25e-05	0.000164	CcSEcCtD
Disopyramide—Malaise—Methotrexate—hematologic cancer	3.22e-05	0.000163	CcSEcCtD
Disopyramide—Dizziness—Etoposide—hematologic cancer	3.22e-05	0.000163	CcSEcCtD
Disopyramide—Vertigo—Methotrexate—hematologic cancer	3.21e-05	0.000162	CcSEcCtD
Disopyramide—Urticaria—Betamethasone—hematologic cancer	3.18e-05	0.000161	CcSEcCtD
Disopyramide—Urticaria—Dexamethasone—hematologic cancer	3.18e-05	0.000161	CcSEcCtD
Disopyramide—Dizziness—Prednisolone—hematologic cancer	3.18e-05	0.00016	CcSEcCtD
Disopyramide—Arrhythmia—Doxorubicin—hematologic cancer	3.18e-05	0.00016	CcSEcCtD
Disopyramide—Asthenia—Triamcinolone—hematologic cancer	3.17e-05	0.00016	CcSEcCtD
Disopyramide—Body temperature increased—Dexamethasone—hematologic cancer	3.17e-05	0.00016	CcSEcCtD
Disopyramide—Body temperature increased—Betamethasone—hematologic cancer	3.17e-05	0.00016	CcSEcCtD
Disopyramide—Nausea—Cisplatin—hematologic cancer	3.16e-05	0.000159	CcSEcCtD
Disopyramide—Insomnia—Prednisone—hematologic cancer	3.16e-05	0.000159	CcSEcCtD
Disopyramide—Vision blurred—Epirubicin—hematologic cancer	3.15e-05	0.000159	CcSEcCtD
Disopyramide—Paraesthesia—Prednisone—hematologic cancer	3.13e-05	0.000158	CcSEcCtD
Disopyramide—Pruritus—Triamcinolone—hematologic cancer	3.13e-05	0.000158	CcSEcCtD
Disopyramide—Ill-defined disorder—Epirubicin—hematologic cancer	3.1e-05	0.000157	CcSEcCtD
Disopyramide—Vomiting—Etoposide—hematologic cancer	3.1e-05	0.000156	CcSEcCtD
Disopyramide—Dyspepsia—Prednisone—hematologic cancer	3.07e-05	0.000155	CcSEcCtD
Disopyramide—Rash—Etoposide—hematologic cancer	3.07e-05	0.000155	CcSEcCtD
Disopyramide—Dermatitis—Etoposide—hematologic cancer	3.07e-05	0.000155	CcSEcCtD
Disopyramide—Headache—Etoposide—hematologic cancer	3.05e-05	0.000154	CcSEcCtD
Disopyramide—Flatulence—Doxorubicin—hematologic cancer	3.05e-05	0.000154	CcSEcCtD
Disopyramide—Chest pain—Methotrexate—hematologic cancer	3.04e-05	0.000154	CcSEcCtD
Disopyramide—Tension—Doxorubicin—hematologic cancer	3.04e-05	0.000153	CcSEcCtD
Disopyramide—Decreased appetite—Prednisone—hematologic cancer	3.03e-05	0.000153	CcSEcCtD
Disopyramide—Dysgeusia—Doxorubicin—hematologic cancer	3.03e-05	0.000153	CcSEcCtD
Disopyramide—Rash—Prednisolone—hematologic cancer	3.03e-05	0.000153	CcSEcCtD
Disopyramide—Dermatitis—Prednisolone—hematologic cancer	3.03e-05	0.000153	CcSEcCtD
Disopyramide—Malaise—Epirubicin—hematologic cancer	3.02e-05	0.000152	CcSEcCtD
Disopyramide—Fatigue—Prednisone—hematologic cancer	3.01e-05	0.000152	CcSEcCtD
Disopyramide—Headache—Prednisolone—hematologic cancer	3.01e-05	0.000152	CcSEcCtD
Disopyramide—Discomfort—Methotrexate—hematologic cancer	3.01e-05	0.000152	CcSEcCtD
Disopyramide—Nervousness—Doxorubicin—hematologic cancer	3.01e-05	0.000152	CcSEcCtD
Disopyramide—Vertigo—Epirubicin—hematologic cancer	3.01e-05	0.000152	CcSEcCtD
Disopyramide—Syncope—Epirubicin—hematologic cancer	3e-05	0.000151	CcSEcCtD
Disopyramide—Constipation—Prednisone—hematologic cancer	2.98e-05	0.000151	CcSEcCtD
Disopyramide—Confusional state—Methotrexate—hematologic cancer	2.94e-05	0.000149	CcSEcCtD
Disopyramide—Loss of consciousness—Epirubicin—hematologic cancer	2.94e-05	0.000148	CcSEcCtD
Disopyramide—Dizziness—Triamcinolone—hematologic cancer	2.92e-05	0.000148	CcSEcCtD
Disopyramide—Vision blurred—Doxorubicin—hematologic cancer	2.92e-05	0.000147	CcSEcCtD
Disopyramide—Nausea—Etoposide—hematologic cancer	2.89e-05	0.000146	CcSEcCtD
Disopyramide—Feeling abnormal—Prednisone—hematologic cancer	2.88e-05	0.000145	CcSEcCtD
Disopyramide—Asthenia—Betamethasone—hematologic cancer	2.88e-05	0.000145	CcSEcCtD
Disopyramide—Asthenia—Dexamethasone—hematologic cancer	2.88e-05	0.000145	CcSEcCtD
Disopyramide—Ill-defined disorder—Doxorubicin—hematologic cancer	2.87e-05	0.000145	CcSEcCtD
Disopyramide—Thrombocytopenia—Methotrexate—hematologic cancer	2.86e-05	0.000144	CcSEcCtD
Disopyramide—Nausea—Prednisolone—hematologic cancer	2.85e-05	0.000144	CcSEcCtD
Disopyramide—Chest pain—Epirubicin—hematologic cancer	2.85e-05	0.000144	CcSEcCtD
Disopyramide—Pruritus—Dexamethasone—hematologic cancer	2.84e-05	0.000143	CcSEcCtD
Disopyramide—Pruritus—Betamethasone—hematologic cancer	2.84e-05	0.000143	CcSEcCtD
Disopyramide—Skin disorder—Methotrexate—hematologic cancer	2.83e-05	0.000143	CcSEcCtD
Disopyramide—Hyperhidrosis—Methotrexate—hematologic cancer	2.82e-05	0.000142	CcSEcCtD
Disopyramide—Discomfort—Epirubicin—hematologic cancer	2.81e-05	0.000142	CcSEcCtD
Disopyramide—Vomiting—Triamcinolone—hematologic cancer	2.81e-05	0.000142	CcSEcCtD
Disopyramide—Malaise—Doxorubicin—hematologic cancer	2.79e-05	0.000141	CcSEcCtD
Disopyramide—Rash—Triamcinolone—hematologic cancer	2.79e-05	0.000141	CcSEcCtD
Disopyramide—Dry mouth—Epirubicin—hematologic cancer	2.78e-05	0.000141	CcSEcCtD
Disopyramide—Dermatitis—Triamcinolone—hematologic cancer	2.78e-05	0.000141	CcSEcCtD
Disopyramide—Vertigo—Doxorubicin—hematologic cancer	2.78e-05	0.00014	CcSEcCtD
Disopyramide—Anorexia—Methotrexate—hematologic cancer	2.78e-05	0.00014	CcSEcCtD
Disopyramide—Syncope—Doxorubicin—hematologic cancer	2.78e-05	0.00014	CcSEcCtD
Disopyramide—Urticaria—Prednisone—hematologic cancer	2.77e-05	0.00014	CcSEcCtD
Disopyramide—Headache—Triamcinolone—hematologic cancer	2.77e-05	0.00014	CcSEcCtD
Disopyramide—Body temperature increased—Prednisone—hematologic cancer	2.76e-05	0.000139	CcSEcCtD
Disopyramide—Confusional state—Epirubicin—hematologic cancer	2.75e-05	0.000139	CcSEcCtD
Disopyramide—Diarrhoea—Betamethasone—hematologic cancer	2.74e-05	0.000138	CcSEcCtD
Disopyramide—Diarrhoea—Dexamethasone—hematologic cancer	2.74e-05	0.000138	CcSEcCtD
Disopyramide—Oedema—Epirubicin—hematologic cancer	2.73e-05	0.000138	CcSEcCtD
Disopyramide—Hypotension—Methotrexate—hematologic cancer	2.73e-05	0.000138	CcSEcCtD
Disopyramide—Loss of consciousness—Doxorubicin—hematologic cancer	2.72e-05	0.000137	CcSEcCtD
Disopyramide—Shock—Epirubicin—hematologic cancer	2.69e-05	0.000136	CcSEcCtD
Disopyramide—Thrombocytopenia—Epirubicin—hematologic cancer	2.67e-05	0.000135	CcSEcCtD
Disopyramide—Skin disorder—Epirubicin—hematologic cancer	2.65e-05	0.000134	CcSEcCtD
Disopyramide—Dizziness—Betamethasone—hematologic cancer	2.65e-05	0.000134	CcSEcCtD
Disopyramide—Dizziness—Dexamethasone—hematologic cancer	2.65e-05	0.000134	CcSEcCtD
Disopyramide—Hyperhidrosis—Epirubicin—hematologic cancer	2.64e-05	0.000133	CcSEcCtD
Disopyramide—Insomnia—Methotrexate—hematologic cancer	2.64e-05	0.000133	CcSEcCtD
Disopyramide—Chest pain—Doxorubicin—hematologic cancer	2.63e-05	0.000133	CcSEcCtD
Disopyramide—Nausea—Triamcinolone—hematologic cancer	2.62e-05	0.000133	CcSEcCtD
Disopyramide—Paraesthesia—Methotrexate—hematologic cancer	2.62e-05	0.000132	CcSEcCtD
Disopyramide—Discomfort—Doxorubicin—hematologic cancer	2.6e-05	0.000131	CcSEcCtD
Disopyramide—Anorexia—Epirubicin—hematologic cancer	2.6e-05	0.000131	CcSEcCtD
Disopyramide—Dyspnoea—Methotrexate—hematologic cancer	2.6e-05	0.000131	CcSEcCtD
Disopyramide—Somnolence—Methotrexate—hematologic cancer	2.59e-05	0.000131	CcSEcCtD
Disopyramide—Dry mouth—Doxorubicin—hematologic cancer	2.58e-05	0.00013	CcSEcCtD
Disopyramide—Dyspepsia—Methotrexate—hematologic cancer	2.57e-05	0.00013	CcSEcCtD
Disopyramide—Hypotension—Epirubicin—hematologic cancer	2.55e-05	0.000129	CcSEcCtD
Disopyramide—Vomiting—Dexamethasone—hematologic cancer	2.55e-05	0.000129	CcSEcCtD
Disopyramide—Vomiting—Betamethasone—hematologic cancer	2.55e-05	0.000129	CcSEcCtD
Disopyramide—Confusional state—Doxorubicin—hematologic cancer	2.55e-05	0.000129	CcSEcCtD
Disopyramide—Decreased appetite—Methotrexate—hematologic cancer	2.54e-05	0.000128	CcSEcCtD
Disopyramide—Rash—Dexamethasone—hematologic cancer	2.53e-05	0.000128	CcSEcCtD
Disopyramide—Rash—Betamethasone—hematologic cancer	2.53e-05	0.000128	CcSEcCtD
Disopyramide—Oedema—Doxorubicin—hematologic cancer	2.53e-05	0.000128	CcSEcCtD
Disopyramide—Dermatitis—Betamethasone—hematologic cancer	2.52e-05	0.000128	CcSEcCtD
Disopyramide—Dermatitis—Dexamethasone—hematologic cancer	2.52e-05	0.000128	CcSEcCtD
Disopyramide—Fatigue—Methotrexate—hematologic cancer	2.51e-05	0.000127	CcSEcCtD
Disopyramide—Headache—Betamethasone—hematologic cancer	2.51e-05	0.000127	CcSEcCtD
Disopyramide—Headache—Dexamethasone—hematologic cancer	2.51e-05	0.000127	CcSEcCtD
Disopyramide—Asthenia—Prednisone—hematologic cancer	2.5e-05	0.000126	CcSEcCtD
Disopyramide—Pain—Methotrexate—hematologic cancer	2.49e-05	0.000126	CcSEcCtD
Disopyramide—Shock—Doxorubicin—hematologic cancer	2.49e-05	0.000126	CcSEcCtD
Disopyramide—Thrombocytopenia—Doxorubicin—hematologic cancer	2.47e-05	0.000125	CcSEcCtD
Disopyramide—Pruritus—Prednisone—hematologic cancer	2.47e-05	0.000125	CcSEcCtD
Disopyramide—Insomnia—Epirubicin—hematologic cancer	2.47e-05	0.000125	CcSEcCtD
Disopyramide—Skin disorder—Doxorubicin—hematologic cancer	2.45e-05	0.000124	CcSEcCtD
Disopyramide—Paraesthesia—Epirubicin—hematologic cancer	2.45e-05	0.000124	CcSEcCtD
Disopyramide—Hyperhidrosis—Doxorubicin—hematologic cancer	2.44e-05	0.000123	CcSEcCtD
Disopyramide—Dyspnoea—Epirubicin—hematologic cancer	2.43e-05	0.000123	CcSEcCtD
Disopyramide—Somnolence—Epirubicin—hematologic cancer	2.43e-05	0.000123	CcSEcCtD
Disopyramide—Anorexia—Doxorubicin—hematologic cancer	2.41e-05	0.000122	CcSEcCtD
Disopyramide—Feeling abnormal—Methotrexate—hematologic cancer	2.4e-05	0.000121	CcSEcCtD
Disopyramide—Dyspepsia—Epirubicin—hematologic cancer	2.4e-05	0.000121	CcSEcCtD
Disopyramide—Diarrhoea—Prednisone—hematologic cancer	2.39e-05	0.000121	CcSEcCtD
Disopyramide—Nausea—Betamethasone—hematologic cancer	2.38e-05	0.00012	CcSEcCtD
Disopyramide—Nausea—Dexamethasone—hematologic cancer	2.38e-05	0.00012	CcSEcCtD
Disopyramide—Decreased appetite—Epirubicin—hematologic cancer	2.37e-05	0.00012	CcSEcCtD
Disopyramide—Hypotension—Doxorubicin—hematologic cancer	2.36e-05	0.000119	CcSEcCtD
Disopyramide—Fatigue—Epirubicin—hematologic cancer	2.35e-05	0.000119	CcSEcCtD
Disopyramide—Pain—Epirubicin—hematologic cancer	2.33e-05	0.000118	CcSEcCtD
Disopyramide—Constipation—Epirubicin—hematologic cancer	2.33e-05	0.000118	CcSEcCtD
Disopyramide—Urticaria—Methotrexate—hematologic cancer	2.32e-05	0.000117	CcSEcCtD
Disopyramide—Dizziness—Prednisone—hematologic cancer	2.31e-05	0.000117	CcSEcCtD
Disopyramide—Body temperature increased—Methotrexate—hematologic cancer	2.31e-05	0.000116	CcSEcCtD
Disopyramide—Insomnia—Doxorubicin—hematologic cancer	2.28e-05	0.000115	CcSEcCtD
Disopyramide—Paraesthesia—Doxorubicin—hematologic cancer	2.27e-05	0.000115	CcSEcCtD
Disopyramide—Dyspnoea—Doxorubicin—hematologic cancer	2.25e-05	0.000114	CcSEcCtD
Disopyramide—Feeling abnormal—Epirubicin—hematologic cancer	2.25e-05	0.000114	CcSEcCtD
Disopyramide—Somnolence—Doxorubicin—hematologic cancer	2.25e-05	0.000113	CcSEcCtD
Disopyramide—Dyspepsia—Doxorubicin—hematologic cancer	2.22e-05	0.000112	CcSEcCtD
Disopyramide—Vomiting—Prednisone—hematologic cancer	2.22e-05	0.000112	CcSEcCtD
Disopyramide—Rash—Prednisone—hematologic cancer	2.2e-05	0.000111	CcSEcCtD
Disopyramide—Dermatitis—Prednisone—hematologic cancer	2.2e-05	0.000111	CcSEcCtD
Disopyramide—Decreased appetite—Doxorubicin—hematologic cancer	2.2e-05	0.000111	CcSEcCtD
Disopyramide—Headache—Prednisone—hematologic cancer	2.19e-05	0.00011	CcSEcCtD
Disopyramide—Fatigue—Doxorubicin—hematologic cancer	2.18e-05	0.00011	CcSEcCtD
Disopyramide—Urticaria—Epirubicin—hematologic cancer	2.17e-05	0.00011	CcSEcCtD
Disopyramide—Constipation—Doxorubicin—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Disopyramide—Pain—Doxorubicin—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Disopyramide—Body temperature increased—Epirubicin—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Disopyramide—Asthenia—Methotrexate—hematologic cancer	2.09e-05	0.000106	CcSEcCtD
Disopyramide—Feeling abnormal—Doxorubicin—hematologic cancer	2.08e-05	0.000105	CcSEcCtD
Disopyramide—Nausea—Prednisone—hematologic cancer	2.07e-05	0.000105	CcSEcCtD
Disopyramide—Pruritus—Methotrexate—hematologic cancer	2.06e-05	0.000104	CcSEcCtD
Disopyramide—Urticaria—Doxorubicin—hematologic cancer	2.01e-05	0.000101	CcSEcCtD
Disopyramide—Body temperature increased—Doxorubicin—hematologic cancer	2e-05	0.000101	CcSEcCtD
Disopyramide—Diarrhoea—Methotrexate—hematologic cancer	2e-05	0.000101	CcSEcCtD
Disopyramide—Asthenia—Epirubicin—hematologic cancer	1.96e-05	9.89e-05	CcSEcCtD
Disopyramide—Pruritus—Epirubicin—hematologic cancer	1.93e-05	9.75e-05	CcSEcCtD
Disopyramide—Dizziness—Methotrexate—hematologic cancer	1.93e-05	9.74e-05	CcSEcCtD
Disopyramide—Diarrhoea—Epirubicin—hematologic cancer	1.87e-05	9.43e-05	CcSEcCtD
Disopyramide—Vomiting—Methotrexate—hematologic cancer	1.85e-05	9.37e-05	CcSEcCtD
Disopyramide—Rash—Methotrexate—hematologic cancer	1.84e-05	9.29e-05	CcSEcCtD
Disopyramide—Dermatitis—Methotrexate—hematologic cancer	1.84e-05	9.28e-05	CcSEcCtD
Disopyramide—Headache—Methotrexate—hematologic cancer	1.83e-05	9.23e-05	CcSEcCtD
Disopyramide—Asthenia—Doxorubicin—hematologic cancer	1.81e-05	9.15e-05	CcSEcCtD
Disopyramide—Dizziness—Epirubicin—hematologic cancer	1.81e-05	9.12e-05	CcSEcCtD
Disopyramide—Pruritus—Doxorubicin—hematologic cancer	1.79e-05	9.03e-05	CcSEcCtD
Disopyramide—Vomiting—Epirubicin—hematologic cancer	1.74e-05	8.77e-05	CcSEcCtD
Disopyramide—Nausea—Methotrexate—hematologic cancer	1.73e-05	8.75e-05	CcSEcCtD
Disopyramide—Diarrhoea—Doxorubicin—hematologic cancer	1.73e-05	8.73e-05	CcSEcCtD
Disopyramide—Rash—Epirubicin—hematologic cancer	1.72e-05	8.69e-05	CcSEcCtD
Disopyramide—Dermatitis—Epirubicin—hematologic cancer	1.72e-05	8.68e-05	CcSEcCtD
Disopyramide—Headache—Epirubicin—hematologic cancer	1.71e-05	8.64e-05	CcSEcCtD
Disopyramide—Dizziness—Doxorubicin—hematologic cancer	1.67e-05	8.44e-05	CcSEcCtD
Disopyramide—Nausea—Epirubicin—hematologic cancer	1.62e-05	8.19e-05	CcSEcCtD
Disopyramide—Vomiting—Doxorubicin—hematologic cancer	1.61e-05	8.11e-05	CcSEcCtD
Disopyramide—Rash—Doxorubicin—hematologic cancer	1.59e-05	8.04e-05	CcSEcCtD
Disopyramide—Dermatitis—Doxorubicin—hematologic cancer	1.59e-05	8.04e-05	CcSEcCtD
Disopyramide—Headache—Doxorubicin—hematologic cancer	1.58e-05	7.99e-05	CcSEcCtD
Disopyramide—Nausea—Doxorubicin—hematologic cancer	1.5e-05	7.58e-05	CcSEcCtD
Disopyramide—SLC22A2—Metabolism—CREBBP—hematologic cancer	4.16e-06	7.46e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—JAK1—hematologic cancer	4.15e-06	7.44e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PRKCG—hematologic cancer	4.15e-06	7.44e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—PIK3CB—hematologic cancer	4.15e-06	7.44e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PDGFRA—hematologic cancer	4.12e-06	7.39e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—TXN—hematologic cancer	4.12e-06	7.38e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCC3—hematologic cancer	4.12e-06	7.38e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTO1—hematologic cancer	4.12e-06	7.38e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PRKCG—hematologic cancer	4.11e-06	7.37e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—JAK1—hematologic cancer	4.11e-06	7.37e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—SPHK1—hematologic cancer	4.03e-06	7.22e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CD—hematologic cancer	3.94e-06	7.07e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—ALB—hematologic cancer	3.89e-06	6.98e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL2RA—hematologic cancer	3.89e-06	6.97e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—CREBBP—hematologic cancer	3.88e-06	6.95e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL2RA—hematologic cancer	3.88e-06	6.95e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—UGT1A1—hematologic cancer	3.87e-06	6.94e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CG—hematologic cancer	3.86e-06	6.92e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—IL2—hematologic cancer	3.86e-06	6.92e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—IL2—hematologic cancer	3.85e-06	6.9e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TERT—hematologic cancer	3.84e-06	6.89e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL2RA—hematologic cancer	3.84e-06	6.88e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TERT—hematologic cancer	3.83e-06	6.87e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL2—hematologic cancer	3.81e-06	6.83e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TERT—hematologic cancer	3.8e-06	6.8e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.77e-06	6.75e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.77e-06	6.75e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	3.75e-06	6.73e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PDGFB—hematologic cancer	3.74e-06	6.71e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3R1—hematologic cancer	3.72e-06	6.68e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PDGFB—hematologic cancer	3.7e-06	6.64e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CD—hematologic cancer	3.68e-06	6.59e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALOX5—hematologic cancer	3.67e-06	6.58e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TSC2—hematologic cancer	3.67e-06	6.58e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TSC2—hematologic cancer	3.66e-06	6.55e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—ALB—hematologic cancer	3.63e-06	6.5e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TSC2—hematologic cancer	3.62e-06	6.49e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—CREBBP—hematologic cancer	3.58e-06	6.42e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NUP98—hematologic cancer	3.55e-06	6.37e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	3.53e-06	6.33e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	3.52e-06	6.31e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	3.49e-06	6.26e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FGFR3—hematologic cancer	3.48e-06	6.24e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	3.48e-06	6.24e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3R1—hematologic cancer	3.47e-06	6.22e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.45e-06	6.18e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.45e-06	6.18e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK14—hematologic cancer	3.45e-06	6.18e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CB—hematologic cancer	3.44e-06	6.16e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—ESR1—hematologic cancer	3.43e-06	6.14e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NUP214—hematologic cancer	3.43e-06	6.14e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—ESR1—hematologic cancer	3.42e-06	6.12e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CD—hematologic cancer	3.39e-06	6.09e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FN1—hematologic cancer	3.39e-06	6.07e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—ESR1—hematologic cancer	3.38e-06	6.06e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FN1—hematologic cancer	3.37e-06	6.05e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—MTR—hematologic cancer	3.36e-06	6.02e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.36e-06	6.02e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—ALB—hematologic cancer	3.35e-06	6.01e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—BAD—hematologic cancer	3.34e-06	6e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	3.34e-06	6e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FN1—hematologic cancer	3.34e-06	5.99e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—BAD—hematologic cancer	3.33e-06	5.98e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	3.33e-06	5.98e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	3.31e-06	5.94e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	3.3e-06	5.92e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—BAD—hematologic cancer	3.3e-06	5.92e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	3.3e-06	5.92e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ENO2—hematologic cancer	3.29e-06	5.9e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	3.27e-06	5.86e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CD80—hematologic cancer	3.25e-06	5.82e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	3.24e-06	5.81e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KIT—hematologic cancer	3.24e-06	5.81e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	3.24e-06	5.81e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CD80—hematologic cancer	3.24e-06	5.8e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KIT—hematologic cancer	3.23e-06	5.79e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	3.23e-06	5.79e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	3.23e-06	5.79e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3R1—hematologic cancer	3.21e-06	5.75e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CD80—hematologic cancer	3.2e-06	5.74e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CB—hematologic cancer	3.2e-06	5.74e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	3.2e-06	5.73e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KIT—hematologic cancer	3.2e-06	5.73e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	3.2e-06	5.73e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTT1—hematologic cancer	3.19e-06	5.72e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	3.18e-06	5.71e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	3.17e-06	5.69e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	3.14e-06	5.63e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—SDC1—hematologic cancer	3.12e-06	5.59e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	3.1e-06	5.56e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	3.09e-06	5.54e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CREB1—hematologic cancer	3.08e-06	5.53e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CREB1—hematologic cancer	3.07e-06	5.51e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	3.06e-06	5.49e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—BRAF—hematologic cancer	3.04e-06	5.46e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CREB1—hematologic cancer	3.04e-06	5.46e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—BRAF—hematologic cancer	3.04e-06	5.44e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CCL2—hematologic cancer	3.02e-06	5.41e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL6R—hematologic cancer	3.01e-06	5.39e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CCL2—hematologic cancer	3.01e-06	5.39e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—BRAF—hematologic cancer	3.01e-06	5.39e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	3e-06	5.38e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL6R—hematologic cancer	3e-06	5.38e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	2.99e-06	5.37e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CCL2—hematologic cancer	2.98e-06	5.34e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PTEN—hematologic cancer	2.97e-06	5.32e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL6R—hematologic cancer	2.97e-06	5.32e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	2.96e-06	5.32e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CB—hematologic cancer	2.96e-06	5.3e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	2.87e-06	5.14e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	2.86e-06	5.12e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	2.85e-06	5.11e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	2.84e-06	5.09e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—EP300—hematologic cancer	2.83e-06	5.08e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	2.83e-06	5.07e-05	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.82e-06	5.06e-05	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	2.81e-06	5.04e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	2.81e-06	5.04e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	2.79e-06	5e-05	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.78e-06	4.99e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	2.78e-06	4.98e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PTEN—hematologic cancer	2.77e-06	4.96e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	2.75e-06	4.93e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FGF2—hematologic cancer	2.73e-06	4.89e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FGF2—hematologic cancer	2.72e-06	4.87e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FGF2—hematologic cancer	2.69e-06	4.83e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	2.69e-06	4.82e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	2.68e-06	4.81e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	2.65e-06	4.76e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CD44—hematologic cancer	2.65e-06	4.76e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NQO1—hematologic cancer	2.65e-06	4.76e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—EP300—hematologic cancer	2.64e-06	4.73e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—JAK2—hematologic cancer	2.61e-06	4.69e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—JAK2—hematologic cancer	2.61e-06	4.67e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—JAK2—hematologic cancer	2.58e-06	4.63e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	2.56e-06	4.59e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PTEN—hematologic cancer	2.56e-06	4.58e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	2.55e-06	4.58e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MDM2—hematologic cancer	2.55e-06	4.57e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MDM2—hematologic cancer	2.54e-06	4.56e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	2.53e-06	4.53e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MDM2—hematologic cancer	2.52e-06	4.51e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYCS—hematologic cancer	2.51e-06	4.5e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.49e-06	4.47e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	2.48e-06	4.45e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MTOR—hematologic cancer	2.48e-06	4.45e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	2.47e-06	4.44e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MTOR—hematologic cancer	2.47e-06	4.44e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MTOR—hematologic cancer	2.45e-06	4.39e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	2.45e-06	4.39e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—EP300—hematologic cancer	2.44e-06	4.37e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	2.37e-06	4.25e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	2.36e-06	4.24e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	2.34e-06	4.19e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	2.33e-06	4.18e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	2.32e-06	4.16e-05	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	2.3e-06	4.13e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	2.3e-06	4.12e-05	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	2.3e-06	4.12e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CASP3—hematologic cancer	2.28e-06	4.09e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL2—hematologic cancer	2.28e-06	4.09e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CASP3—hematologic cancer	2.28e-06	4.08e-05	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	2.27e-06	4.08e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL2—hematologic cancer	2.27e-06	4.07e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—IL6—hematologic cancer	2.27e-06	4.07e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—IL6—hematologic cancer	2.26e-06	4.05e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CASP3—hematologic cancer	2.25e-06	4.04e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL2—hematologic cancer	2.25e-06	4.03e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL6—hematologic cancer	2.24e-06	4.01e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CCND1—hematologic cancer	2.22e-06	3.98e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—JUN—hematologic cancer	2.22e-06	3.98e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CCND1—hematologic cancer	2.22e-06	3.97e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.21e-06	3.97e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—JUN—hematologic cancer	2.21e-06	3.96e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CCND1—hematologic cancer	2.19e-06	3.93e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—JUN—hematologic cancer	2.19e-06	3.92e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	2.15e-06	3.85e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PTEN—hematologic cancer	2.14e-06	3.85e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	2.14e-06	3.84e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PTEN—hematologic cancer	2.14e-06	3.83e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	2.12e-06	3.8e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PTEN—hematologic cancer	2.12e-06	3.8e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	2.1e-06	3.76e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CA—hematologic cancer	2.1e-06	3.76e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.09e-06	3.75e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	2.09e-06	3.75e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	2.09e-06	3.75e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	2.09e-06	3.74e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	2.07e-06	3.71e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	2.07e-06	3.7e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EP300—hematologic cancer	2.05e-06	3.67e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EP300—hematologic cancer	2.04e-06	3.66e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.03e-06	3.64e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.03e-06	3.64e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EP300—hematologic cancer	2.02e-06	3.62e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—SRC—hematologic cancer	1.99e-06	3.57e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—SRC—hematologic cancer	1.98e-06	3.55e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—SRC—hematologic cancer	1.96e-06	3.52e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CA—hematologic cancer	1.95e-06	3.5e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	1.94e-06	3.47e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	1.93e-06	3.46e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—STAT3—hematologic cancer	1.92e-06	3.44e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NRAS—hematologic cancer	1.91e-06	3.43e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	1.91e-06	3.43e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—STAT3—hematologic cancer	1.91e-06	3.43e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NRAS—hematologic cancer	1.91e-06	3.42e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—STAT3—hematologic cancer	1.89e-06	3.39e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NRAS—hematologic cancer	1.89e-06	3.39e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	1.83e-06	3.29e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	1.83e-06	3.28e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	1.81e-06	3.24e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CA—hematologic cancer	1.8e-06	3.23e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.8e-06	3.22e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MYC—hematologic cancer	1.78e-06	3.2e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	1.78e-06	3.19e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MYC—hematologic cancer	1.78e-06	3.19e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	1.77e-06	3.18e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MYC—hematologic cancer	1.76e-06	3.15e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	1.76e-06	3.15e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—AKT1—hematologic cancer	1.71e-06	3.07e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KRAS—hematologic cancer	1.65e-06	2.95e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KRAS—hematologic cancer	1.64e-06	2.94e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KRAS—hematologic cancer	1.63e-06	2.91e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—AKT1—hematologic cancer	1.6e-06	2.86e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.51e-06	2.71e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.51e-06	2.71e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	1.51e-06	2.7e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	1.49e-06	2.68e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—AKT1—hematologic cancer	1.47e-06	2.64e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TP53—hematologic cancer	1.46e-06	2.62e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TP53—hematologic cancer	1.46e-06	2.62e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TP53—hematologic cancer	1.45e-06	2.59e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—HRAS—hematologic cancer	1.4e-06	2.51e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.4e-06	2.51e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—HRAS—hematologic cancer	1.4e-06	2.5e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—HRAS—hematologic cancer	1.38e-06	2.48e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL6—hematologic cancer	1.34e-06	2.4e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL6—hematologic cancer	1.34e-06	2.39e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.33e-06	2.38e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL6—hematologic cancer	1.32e-06	2.37e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALB—hematologic cancer	1.31e-06	2.35e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.25e-06	2.25e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.24e-06	2.22e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—AKT1—hematologic cancer	1.23e-06	2.21e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—AKT1—hematologic cancer	1.22e-06	2.19e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.16e-06	2.07e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTEN—hematologic cancer	1e-06	1.79e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—EP300—hematologic cancer	9.53e-07	1.71e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	7.05e-07	1.26e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—AKT1—hematologic cancer	5.76e-07	1.03e-05	CbGpPWpGaD
